Medical News

RSS

View News A-Z »

Political cartoon: 'Fear Itself'

Kaiser Health News provides a fresh take on health policy developments with "Fear Itself" by Steve Kelley.

6 Aug 2012

Premier healthcare alliance awards new agreements for mobility aids

The Premier healthcare alliance today announced new agreements for mobility aids have been awarded.

6 Aug 2012

Qualitest confirms launch of generic Singulair Tablets for asthma and allergic rhinitis

Qualitest Pharmaceuticals today confirmed that it has launched a generic version of Singulair (montelukast sodium) Tablets and Chewable Tablets, following the expiration of the last patent that provides Merck U.S. market exclusivity. Qualitest will begin shipping the product immediately. Montelukast Sodium Tablets are labeled for use in treating symptoms of asthma and allergic rhinitis.

6 Aug 2012

Blog examines impact of adolescent pregnancy in South Asia

As part of its monthly series Stories Behind the Statistics, "guest edited by FHI 360 on behalf of USAID'S IYWG, which provides technical leadership to improve the reproductive and sexual health of young people," the Bill & Melinda Gates Foundation's "Impatient Optimists" blog features a story by Gaj Bahadur Gurung, program coordinator for the National Federation of Women Living with HIV and AIDS in Nepal, who discusses the impact of adolescent pregnancy on girls and young women in South Asia.

6 Aug 2012

Medical devices for diabetic peripheral neuropathy: an interview with Dr. Shai Gozani, CEO of NeuroMetrix

About two years ago NeuroMetrix changed their focus from general purpose devices, used to perform nerve conduction tests, to devices designed to specifically address diabetic peripheral neuropathy or DPN.

6 Aug 2012

Head trauma in older adults over a weekend more deadly than during the week

A Johns Hopkins review of more than 38,000 patient records finds that older adults who sustain substantial head trauma over a weekend are significantly more likely to die from their injuries than those similarly hurt and hospitalized Monday through Friday, even if their injuries are less severe and they have fewer other illnesses than their weekday counterparts.

6 Aug 2012

NeoGenomics introduces new molecular assay that detects SF3B1 gene mutations

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today that it has validated and launched the first molecular assay for clinical use in the United States that detects mutations in the SF3B1 gene (splicing factor 3b, subunit 1).

6 Aug 2012

Nanobiotix, PharmaEngine partner to develop NBTXR3 for cancer

French Nanobiotix S.A. announced today that it entered into a strategic partnership with PharmaEngine, Inc. for the rapid development of NBTXR3, the lead product from the NanoXray pipeline of Nanobiotix.

6 Aug 2012

Eliza receives U.S. patent allowance for Complex Acoustic Resonance Speech Analysis System

Eliza Corporation, the pioneer and recognized leader in Health Engagement Management, today announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for a Complex Acoustic Resonance Speech Analysis System.

6 Aug 2012

Mylan receives final FDA approval for generic Amidate ANDA

Mylan Inc. today announced that its business Mylan Institutional has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Etomidate Injection USP, 2 mg/mL packaged in 40 mg/20 mL single-use vials.

6 Aug 2012

First Edition: August 6, 2012

Today's headlines include a progress a report about health insurance exchanges as well as news from the campaign trail.

6 Aug 2012

Mylan launches 18 antiretroviral products in India to treat HIV/AIDS

Mylan Inc., one of the world's leading generic and specialty pharmaceutical companies, today announced that its subsidiary, Mylan Pharmaceuticals Private Limited, has commenced commercial operations in India, starting with the launch of a comprehensive portfolio of 18 antiretroviral (ARV) products for the treatment of HIV/AIDS.

6 Aug 2012

Nanobiotix, PharmaEngine partner to commercialize NBTXR3 for soft tissue sarcoma

PharmaEngine, Inc. announced today the execution of an exclusive license and collaboration agreement with France-based Nanobiotix S.A. for the development and commercialization of NBTXR3, currently being investigated in a phase I study with soft tissue sarcoma patients.

6 Aug 2012

Aquapharm discovers new antibiotic compound against multi-drug resistant bacteria

A significant discovery in the development of next-generation antibiotics has been made by Scottish biotechnology company Aquapharm.

6 Aug 2012

TWi Pharmaceuticals completes AC-201 phase II study on type II diabetes

TWi Pharmaceuticals, Inc., a specialty pharmaceutical company based in Taiwan, today announced its fully owned subsidiary, TWi Biotechnology, Inc. has completed a multinational phase II dose-ranging study of AC-201, an orally available IL-1 Beta modulator, in 259 patients with type II diabetes uncontrolled on up to three oral medications.

6 Aug 2012

Clovis Oncology, Foundation Medicine enter diagnostic collaboration

Foundation Medicine, Inc. and Clovis Oncology, Inc. announced today that they have entered into a diagnostic collaboration.

6 Aug 2012

Medicines with the same active ingredient and size of dose will work the same in the body

In the wake of reports that a number of medicines will increase in price this week, NPS MedicineWise is reminding Australians that while the cost of a medicine may differ from brand to brand, if the active ingredient and size of the dose are the same then the medicine will work the same in their body.

6 Aug 2012

Common ragweed may induce airways irritation through terpenoids

Allergy to pollen of common ragweed is increasingly affecting patients and is second only to grass pollen in terms of incidence in the general population of many European countries.

6 Aug 2012

Medication reconciliation in hospitals: an interview with Dr. Leonard Feldman

Adverse drug effects are harms caused by the use of a medication. There are many different types of ADEs, including medication errors.

6 Aug 2012

Vitamin E total knee replacement performed at Tri-City Medical Center

Dr. James Helgager, an experienced orthopedic surgeon, implanted the first vitamin E Total Knee Replacement in San Diego County on July 31 at Tri-City Medical Center in Oceanside. Helgager is the Medical Director of Joint Replacement for the Orthopaedic & Spine Institute at Tri-City Medical Center. He has been practicing medicine for more than three decades and has performed thousands of total knee replacements.

6 Aug 2012